MedDataX Logo

Case-Control Viramune (Nevirapine) Toxicogenomics Study

NCT ID: NCT00310843

Last Updated: 2013-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

889 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Attempt to identify genetic polymorphisms in interrogated pathways which may be associated with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within the first 8 weeks of nevirapine therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients

NCT02184078

HIV Infections
COMPLETED PHASE4

Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients

NCT02184286

HIV Infections
TERMINATED PHASE1

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

NCT00819052

HIV Infections
COMPLETED PHASE3

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

NCT02194179

HIV Infections
COMPLETED PHASE1

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

NCT00002368

HIV Infections
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All study population

Nevirapine

Intervention Type DRUG

Patients with HIV-1 infection who have taken or are currently taking nevirapine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nevirapine

Patients with HIV-1 infection who have taken or are currently taking nevirapine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion for Case

1. Male or female patients \>=18 years of age with HIV-1 infection who experienced one or more of the following adverse reactions within the first 8 weeks of starting nevirapine therapy:

* Grade 3 or 4 LFT elevation (ALT or AST \> 5X ULN) and any symptom consistent with clinical hepatitis (see Appendix 10.1)
* Acute liver failure secondary to nevirapine therapy\*
* Functional group III or IV rash
* \*Acute liver failure is defined as serious liver injury usually requiring hospitalization that may lead to death or liver transplantation.

Inclusion for Control

Exclusion Criteria

Exclusion for Cases

1. Patients with any hepatotoxicity or rash event which in the investigators judgement is not related to nevirapine use (ex. hepatotoxicity due to alcohol or other medicinal use or rash due to other medicinal use).
2. Patients who began abacavir or TMP-SMX (trimethoprim/sulfamethoxazole) therapy 2 weeks or less prior to or up to 8 weeks after initiating nevirapine therapy.
3. Patients with AST or ALT elevations \> 5 times the ULN (\>= Grade 3) just prior to the initiation of nevirapine therapy.

Exclusion for Controls
4. Patients who discontinued nevirapine before completing 18 weeks of dosing with 200 mg/day for 2 weeks followed by 400 mg/day thereafter.
5. Patients who developed functional group I, IIa or IIb rash within 18 weeks of starting nevirapine therapy, or any dermatologic condition that could plausibly be attributed to nevirapine.
6. Patients with ALT or AST elevations \>2.5 X ULN (\>Grade 1) within 18 weeks of starting nevirapine therapy.
7. Any hepatobiliary adverse event that could possibly be attributed to nevirapine.
8. Patients who develop any systemic reaction attributable to nevirapine use during the first 18 weeks of nevirapine treatment such as flu-like symptoms, arthralgia, myalgia, or conjunctivitis.

Exclusion for Cases and Controls
9. Patients who have participated in the 2NN-Long-term Follow-up study (1100.1454)
10. Patients with CD4 count 150 cells/mm3 prior to the initiation of nevirapine therapy (last available result measured 6 months prior to the initiation of nevirapine therapy).
11. Evidence of acute co-infection with viral hepatitis.
12. Patients taking prednisone, prednisolone, or immuno-modulatory medication within the first 8 weeks of nevirapine therapy.
13. Patients who are unwilling to provide blood samples for DNA testing.
14. Patients who did not sign informed consent and or authorization to release protected health information per local requirements.
15. Patients without available liv
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1100.1452.01006 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

1100.1452.01013 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

1100.1452.99999 Boehringer Ingelheim Investigational Site

Baltimore, Connecticut, United States

Site Status

1100.1452.01011 Boehringer Ingelheim Investigational Site

New Haven, Connecticut, United States

Site Status

1100.1452.01003 Boehringer Ingelheim Investigational Site

Baltimore, Maryland, United States

Site Status

1100.1452.01002 Boehringer Ingelheim Investigational Site

Boston, Massachusetts, United States

Site Status

1100.1452.01014 Boehringer Ingelheim Investigational Site

Springfield, Massachusetts, United States

Site Status

1100.1452.01015 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

1100.1452.01016 Boehringer Ingelheim Investigational Site

New York, New York, United States

Site Status

1100.1452.01012 Boehringer Ingelheim Investigational Site

Chapel Hill, North Carolina, United States

Site Status

1100.1452.01001 Boehringer Ingelheim Investigational Site

Nashville, Tennessee, United States

Site Status

1100.1452.01004 Boehringer Ingelheim Investigational Site

Fort Worth, Texas, United States

Site Status

1100.1452.54001 Fundación Huésped

Capital Federal, , Argentina

Site Status

1100.1452.54002 Funcei

Capital Federal, , Argentina

Site Status

1100.1452.54003 Boehringer Ingelheim Investigational Site

Capital Federal, , Argentina

Site Status

1100.1452.54004 Boehringer Ingelheim Investigational Site

Rosario, , Argentina

Site Status

1100.1452.61004 Boehringer Ingelheim Investigational Site

Darlinghurst, New South Wales, Australia

Site Status

1100.1452.61005 Boehringer Ingelheim Investigational Site

Darlinghurst, New South Wales, Australia

Site Status

1100.1452.61006 Boehringer Ingelheim Investigational Site

Darlinghurst, New South Wales, Australia

Site Status

1100.1452.61003 Boehringer Ingelheim Investigational Site

Miami, Queensland, Australia

Site Status

1100.1452.61002 Boehringer Ingelheim Investigational Site

Carlton, Victoria, Australia

Site Status

1100.1452.61008 Boehringer Ingelheim Investigational Site

Melbourne, Victoria, Australia

Site Status

1100.1452.61001 Boehringer Ingelheim Investigational Site

South Yarra, Victoria, Australia

Site Status

1100.1452.01501 St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

1100.1452.01504 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

1100.1452.01502 Toronto General Hospital

Toronto, Ontario, Canada

Site Status

1100.1452.3304A Hôpital Saint André

Bordeaux, , France

Site Status

1100.1452.3306A Hôpital Hôtel Dieu

Lyon, , France

Site Status

1100.1452.3306B Hop Hôtel Dieu

Lyon, , France

Site Status

1100.1452.3311A Hôpital Edouard Herriot

Lyon, , France

Site Status

1100.1452.3311B Pavillon P

Lyon, , France

Site Status

1100.1452.3311C Hôpital Edouard Herriot

Lyon, , France

Site Status

1100.1452.3311D Hôpital Edouard Herriot

Lyon, , France

Site Status

1100.1452.3305A Hôpital hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305B Hôpital hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305C Hôpital hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305D Hôpital Hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305E Hôpital hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305F Hôpital Hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305G Hôpital Hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305H Hôpital hôtel Dieu

Nantes, , France

Site Status

1100.1452.3305I Hôpital Hôtel Dieu

Nantes, , France

Site Status

1100.1452.3301A Hôpital Saint Louis

Paris, , France

Site Status

1100.1452.3302A Hôpital Tenon

Paris, , France

Site Status

1100.1452.3303A Hôpital de la Pité Salpêtrière

Paris, , France

Site Status

1100.1452.3310A Hôpital Bichat Claude Bernard

Paris, , France

Site Status

1100.1452.3310B Hôpital Bichat Claude Bernard

Paris, , France

Site Status

1100.1452.3313A Hôpital Saint Antoine

Paris, , France

Site Status

1100.1452.3313B Hôpital Saint Antoine

Paris, , France

Site Status

1100.1452.3313C Hôpital Saint Antoine

Paris, , France

Site Status

1100.1452.3314A Hôpital Européen Georges Pompidou

Paris, , France

Site Status

1100.1452.3308A Hôpital Purpan

Toulouse, , France

Site Status

1100.1452.3308B Hôpital Purpan

Toulouse, , France

Site Status

1100.1452.3307A Hôpital Guy Chateliez

Tourcoing, , France

Site Status

1100.1452.3307B Hôpital Guy Chateliez

Tourcoing, , France

Site Status

1100.1452.3307C Hôpital Guy Chateliez

Tourcoing, , France

Site Status

1100.1452.3307D Hôpital Guy Chateliez

Tourcoing, , France

Site Status

1100.1452.3307E Hôpital Guy Chateliez

Tourcoing, , France

Site Status

1100.1452.3312A Hôpital Brabois

Vandœuvre-lès-Nancy, , France

Site Status

1100.1452.4901 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1100.1452.4902 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1100.1452.9907 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

1100.1452.4903 Boehringer Ingelheim Investigational Site

Bochum, , Germany

Site Status

1100.1452.4918 Boehringer Ingelheim Investigational Site

Bonn, , Germany

Site Status

1100.1452.4912 Boehringer Ingelheim Investigational Site

Düsseldorf, , Germany

Site Status

1100.1452.4904 Boehringer Ingelheim Investigational Site

Essen, , Germany

Site Status

1100.1452.4933 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

1100.1452.4916 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1100.1452.4931 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

1100.1452.4910 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

1100.1452.4900 Universitätsklinikum Ulm

Ulm, , Germany

Site Status

1100.1452.4932 Boehringer Ingelheim Investigational Site

Würzburg, , Germany

Site Status

1100.1452.31001 Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

1100.1452.31002 Onze Lieve Vrouwen Gasthuis

Amsterdam, , Netherlands

Site Status

1100.1452.34005 Boehringer Ingelheim Investigational Site

Badalona, , Spain

Site Status

1100.1452.34001 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1452.34002 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1452.34004 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1100.1452.34003 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat, , Spain

Site Status

1100.1452.34006 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1452.34007 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1452.34010 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1452.34011 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1100.1452.34009 Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

1100.1452.88602 Kaohsiung Veterans General Hospital

Kaohsiung City, , Taiwan

Site Status

1100.1452.88603 E-Da Hospital

Kaohsiung City, , Taiwan

Site Status

1100.1452.88605 Chung-Ho Memorial Hospital, Kaohsiung Medical University

Kaohsiung City, , Taiwan

Site Status

1100.1452.88606 China Medical University Hospital

Taichung, , Taiwan

Site Status

1100.1452.88601 National Taiwan University Hospital

Taipei, , Taiwan

Site Status

1100.1452.88604 Taipei City Hospital

Taipei, , Taiwan

Site Status

1100.1452.66001 Boehringer Ingelheim Investigational Site

Bangkok, , Thailand

Site Status

1100.1452.66002 Boehringer Ingelheim Investigational Site

Bangkok, , Thailand

Site Status

1100.1452.66003 Boehringer Ingelheim Investigational Site

Khon Kaen, , Thailand

Site Status

1100.1452.44006 Boehringer Ingelheim Investigational Site

Birmingham, , United Kingdom

Site Status

1100.1452.44004 Boehringer Ingelheim Investigational Site

Brighton, , United Kingdom

Site Status

1100.1452.44001 Boehringer Ingelheim Investigational Site

Coventry, , United Kingdom

Site Status

1100.1452.44002 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1452.44005 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1452.44008 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1452.44009 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

1100.1452.44003 Boehringer Ingelheim Investigational Site

Manchester, , United Kingdom

Site Status

1100.1452.44007 Boehringer Ingelheim Investigational Site

Plaistow, London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Canada France Germany Netherlands Spain Taiwan Thailand United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2005-004321-26

Identifier Type: -

Identifier Source: secondary_id

1100.1452

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
NCT02182765 TERMINATED PHASE1
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
NCT00561925 COMPLETED PHASE3
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
NCT00000747 COMPLETED PHASE2
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
NCT01524900 COMPLETED
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
NCT00002381 COMPLETED PHASE1
Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
NCT00979420 COMPLETED
Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients
NCT00543803 COMPLETED
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
NCT00000962 COMPLETED PHASE1
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
NCT06061081 TERMINATED PHASE2
EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
NCT01886404 COMPLETED
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
NCT02346084 COMPLETED PHASE1
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.
NCT00002194 COMPLETED PHASE1
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
NCT00876733 COMPLETED
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
NCT00643643 COMPLETED PHASE2
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
NCT02202005 COMPLETED PHASE1
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
NCT00001087 COMPLETED PHASE2
A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
NCT00344461 COMPLETED PHASE4
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
NCT01097070 COMPLETED PHASE2
TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
NCT00910806 COMPLETED PHASE1
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
NCT00000806 COMPLETED PHASE1
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
NCT00002418 TERMINATED PHASE2
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients
NCT02184299 COMPLETED PHASE4
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
NCT02187107 COMPLETED PHASE2
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children
NCT00000634 COMPLETED NA
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
NCT00000814 COMPLETED PHASE1